Zenas BioPharma, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on the development and commercialization of immunology-based therapies for patients with autoimmune diseases. The company advances a pipeline featuring its lead candidate obexelimab, a bifunctional monoclonal antibody that binds CD19 and FcγRIIb to suppress B cell activity without depletion in indications including immunoglobulin G4-related disease (IgG4-RD) in the ongoing Phase 3 INDIGO trial, relapsing multiple sclerosis (RMS) with Phase 2 MoonStone data expected in Q1 2026, and systemic lupus erythematosus (SLE) in the Phase 2 SunStone trial; orelabrutinib, a CNS-penetrant oral BTK inhibitor licensed globally ex-oncology from InnoCare Pharma in October 2025 for primary progressive multiple sclerosis (PPMS) in a Phase 3 trial and secondary progressive MS (SPMS) with initiation planned for Q1 2026; and earlier programs such as ZB002 (anti-TNFα monoclonal antibody), ZB004 (CTLA-4-Ig fusion protein), ZB001 (anti-IGF-1R monoclonal antibody, licensed to Zai Lab in Greater China), ZB021, and ZB022. Founded in 2020 and headquartered in Waltham, Massachusetts, Zenas BioPharma conducts global clinical trials across approximately 20 countries and targets unmet needs in immune-mediated inflammatory diseases for patients worldwide. Recent developments include a transformative October 2025 license agreement with InnoCare Pharma granting global rights to orelabrutinib backed by a $120 million private placement funding operations into Q4 2026, a September 2025 funding deal with Royalty Pharma for up to $300 million in obexelimab royalties to support late-stage development and commercialization, completion of enrollment in the IgG4-RD Phase 3 trial with topline data anticipated by year-end 2025, and an expanded Series C financing of $458 million in 2024 to fuel growth.
Company News
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026
Zenas BioPharma to Host Virtual R&D Event
Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Analyzing United Therapeutics (NASDAQ:UTHR) and Zenas BioPharma (NASDAQ:ZBIO)
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Bank of America Corp DE Purchases 341,187 Shares of Zenas BioPharma, Inc. $ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Financial Review: Arcturus Therapeutics (NASDAQ:ARCT) vs. Zenas BioPharma (NASDAQ:ZBIO)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)